Zhou et al. demonstrate that perineural invasion (PNI) is an adverse prognostic factor in small cell lung cancer. They identify a neuron-STMN2-β-alanine axis, where the neural microenvironment upregulates STMN2 in tumor cells, reprogramming β-alanine metabolism to enhance cell migration and drive neural invasion, revealing a potential therapeutic target.
Myelination is increasingly recognized as a dynamic and adaptive process regulated by oligodendrocytes throughout life. Beyond providing electrical insulation, myelin supports axonal metabolism and may serve as an energy reservoir under metabolic stress, highlighting the importance of physiological myelin turnover. Dysregulation of myelin dynamics contributes to a wide spectrum of neurological disorders, including demyelinating, neurodegenerative, and neuropsychiatric diseases. Growing evidence indicates that neurotransmitter signaling through G protein-coupled receptors (GPCRs) expressed by oligodendrocyte lineage cells regulates myelin formation, remodeling, and repair.
Li et al. use multimodal MRI to show that cerebral blood volume is inversely correlated with glymphatic influx across six brain states. Lower CBV is associated with expanded extra-ventricular CSF space, and caffeine produces a similar pattern in awake mice, suggesting CBV as a tonic vascular factor complementing pulsation and vasomotion.
Glioblastoma (GBM) is the most common and aggressive malignant brain tumor. Standard treatments including surgical resection, radiotherapy, and chemotherapy, have failed to significantly improve the prognosis of glioblastoma patients. Currently, immunotherapeutic approaches based on vaccines, chimeric antigen-receptor T-cells, checkpoint inhibitors, and oncolytic virotherapy are showing promising results in clinical trials. The combination of different immunotherapeutic approaches is proving satisfactory and promising. In view of the challenges of immunotherapy and the resistance of glioblastomas, the treatment of these tumors requires further efforts. In this review, we explore the obstacles that potentially influence the efficacy of the response to immunotherapy and that should be taken into account in clinical trials.
Our memories of past events are typically not isolated, but they are linked to other related memories. This ability to establish connections between related memories is highly advantageous, as it helps us to recognize familiar patterns in new situations and make predictions that can inform our decisions.
Researchers at UCLA’s Brain Research Institute recently carried out a study on mice aimed at better understanding how the brain decides what memories are connected and which ones are not. Their paper, published in Nature Neuroscience, pinpoints brain regions that could play a role in the organization of memories into coherent pools of knowledge.
“Our lab has long been interested in understanding how the brain connects related memories,” André F. de Sousa, first author of the paper, told Medical Xpress. “In everyday life, new experiences are rarely processed in isolation. Instead, they are often shaped by what we have learned before. This ability allows us to link related events, build knowledge, and use past experiences to guide future behavior. However, this process needs to be carefully controlled.”
A novel, noninvasive brain stimulation approach—known as transcranial temporal interference stimulation (TIs)—may offer a new way to treat motor symptoms in Parkinson’s disease without the need for surgery, according to a pilot study appearing in eBioMedicine. The technique, which uses overlapping electrical currents to selectively target deep brain regions, significantly improved movement in patients compared with a sham treatment when targeting the subthalamic nucleus.
Parkinson’s disease is a progressive neurological disorder that affects movement, often causing tremor, stiffness, and slowed motion. One of the most effective treatments for advanced symptoms is deep brain stimulation (DBS), which involves implanting electrodes into the brain. TIs may be able to achieve a similar effect—targeting the same deep brain structures —but entirely from outside the skull, using carefully calibrated electrical fields delivered through the scalp.
In the randomized, double-blind, crossover study, titled “Transcranial temporal interference stimulation targeting the subthalamic region for motor symptoms in Parkinson’s disease: a pilot, randomised, double-blind, sham-controlled crossover study,” 30 people with early-to mid-stage Parkinson’s disease received a single 20-minute session of individualized TIs targeting the subthalamic region—a key node in the brain’s motor control network—as well as a sham or placebo treatment in a separate session.